Mirum's rare liver disease drug meets main goal in mid-stage study

Mirum Pharmaceuticals said on Monday its experimental drug, volixibat, met the main goal of ​a mid-stage study by reducing severe itching ‌or pruritus in patients with a type of rare liver disease.